Market Access Deal finally unlocks NHS access to ITF’s Duchenne drug PharmaphorumAfter nearly two years of wrangling, ITF's Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy.Rare DiseaseRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) Pharmaphorum After nearly two years of wrangling, ITF’s Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BMS’ Sotyktu secures EC approval for psoriatic arthritisNext: Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher Related Stories Market Access pharminent June 12, 2026 Market Access Aquipta recommended by NICE for acute migraine treatment pharminent June 10, 2026 Market Access AbbVie’s migraine drug cleared for migraine attacks on NHS pharminent June 10, 2026
